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Abstract
Background: Rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis are immune-mediated
inflammatory diseases with similarities in pathophysiology, and all can be treated with similar biological agents.
Previous studies have shown that there are gender differences with regard to disease characteristics in RA and IBD,
with women generally having worse scores on pain and quality of life measurements. The relationship is less clear
for psoriasis. Because treatment differences between men and women could explain the dissimilarities, we
investigated gender differences in the disease characteristics before treatment initiation and in the biologic
treatment prescribed.
Methods: Data on patients with RA or IBD were collected from two registries in which patients treated with
biologic medication were enrolled. Basic demographic data and disease activity parameters were collected from a
time point just before the initiation of the biologic treatment. For patients with psoriasis, the data were taken from
the 2010 annual report of the Swedish Psoriasis Register for systemic treatment, which included also non-biologic
treatment. For all three diseases, the prescribed treatment and disease characteristics were compared between
men and women.
Results: In total, 4493 adult patients were included in the study (1912 with RA, 131 with IBD, and 2450 with
psoriasis). Most of the treated patients with RA were women, whereas most of the patients with IBD or psoriasis
were men. There were no significant differences between men and women in the choice of biologics. At
treatment start, significant gender differences were seen in the subjective disease measurements for both RA and
psoriasis, with women having higher (that is, worse) scores than men. No differences in objective measurements
were found for RA, but for psoriasis men had higher (that is, worse) scores for objective disease activity measures.
A similar trend to RA was seen in IBD.
Conclusions: Women with RA or psoriasis scored significantly higher on subjective, but not on objective, disease
activity measures than men, and the same trend was seen in IBD. This indicates that at the same level of
treatment, the disease has a greater effect in women. These findings might suggest that in all three diseases,
subjective measures are discounted to some extent in the therapeutic decision-making process, which could
indicate undertreatment in female patients.
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Background
Rheumatoid arthritis (RA) is a chronic systemic disease
that affects the synovial joints. Joint inflammation may
lead to progressive destruction of bone and cartilage,
which eventually causes loss of function and disability [1].
To control symptoms and prevent joint damage, treatment
with disease-modifying antirheumatic drugs (DMARDs)
such as methotrexate and sulfasalazine, is the cornerstone
of RA management. More recent treatments include biolo-
gic drugs of which anti-tumor necrosis factor (anti-TNF)
agents are the most frequently used [1,2].
The expression and clinical course of RA are influenced
by gender. In developed countries the prevalence of RA is
0,5 to 1.0%, with a male:female ratio of 1:3. The reason
for this imbalance is not clear, but both genetic and hor-
monal factors are thought to be involved. In most studies
focusing on the relationship between gender and RA,
women were found to have higher disease activity scores,
more pain and greater loss of function, both in early and
established disease [3-6]. Other studies have reported fas-
ter progression of disability in women as measured by
the Health Assessment Questionnaire (HAQ), and a
lower remission rate in women with early RA [3,7].
Although these studies suggest a less favorable course in
women, there is also evidence to the contrary. One study
found that erosive disease (that is, severe joint destruc-
tion) was more common in men, and also occurred ear-
lier in the disease course. However, women underwent
more surgical operations to correct the consequences of
joint destruction [8].
Crohn’s disease (CD) and ulcerative colitis (UC) are
two of the most common forms of inflammatory bowel
disease (IBD), a group of chronic systemic diseases caus-
ing inflammation of the gastrointestinal tract. UC affects
only the large bowel, whereas CD can involve the whole
gastrointestinal tract. In the treatment of IBD, corticos-
teroids, aminosalicylates, and immunosuppressive agents
are used to induce and remain long-term remission.
When these fail to achieve sufficient disease control, bio-
logic agents can be used, with infliximab being the most
widely used biologic in IBD treatment [9]. The literature
concerning gender and IBD is relatively limited and to
some extent contradictory. The male:female incidence
ratio is estimated to be around 1:1.5 for IBD [10]. Female
gender was reported to be a risk factor for earlier recur-
rence of CD after surgery in two studies [10,11], but male
gender was found to be a greater risk in another study
[12]. Gender was not a prognostic factor for disease
course [13]. IBD is associated with an increased risk of
colorectal cancer, but this risk seems to be lower in
females [14].
Psoriasis encompasses a group of chronic, immune-
mediated inflammatory skin and joint diseases, of which
chronic plaque psoriasis is the most common form. In
the treatment of psoriasis, topical agents are used first,
followed by or in combination with phototherapy and/or
finally systemic therapy [15]. Both non-biologic (metho-
trexate, acitretin, cyclosporine and UV therapy) and bio-
logic agents (etanercept, adalimumab, infliximab and
ustekinumab) can be used as systemic therapy [16].
There is no difference in the male:female ratio, with an
estimated prevalence of 2% for both sexes [17]. A few
studies on health -related quality of life (HRQOL) have
suggested that with the same degree of skin disease,
women experience more stigmatization and worse
HRQOL [18,19]; however, a systemic review did not
find any relationship between gender and quality of life
[20].
Thus, there is some evidence for gender differences in
all three of these immune-mediated inflammatory dis-
eases. In previous studies, a number of explanations have
been given for these gender differences, including that
they are caused by differences in the treatment given to
men and women. Therefore, we investigated gender dif-
ferences in treatment by analyzing disease characteristics
just before initiation of biologic therapy in patients with
RA, IBD, or psoriasis.
Methods
Patient consent for data registry and subsequent use in
research was obtained from patients at the time of inclu-
sion in all three registries, and local ethics committees
approved the use of the data for these studies.
Patients
For this observational study, adult patients with RA,
psoriasis or IBD who were treated with biologic agents
(etanercept, adalimumab, infliximab, rituximab, abata-
cept, golimumab, certolizumab pegol, anakinra, tocilizu-
mab, and ustekinumab) between 1999 and 2010 were
included. Only the first prescribed biologic for each
patient was considered.
Data on patients with RA or IBD were obtained from
two different registries in Sweden: the Stockholm TNF
follow-Up Registry (STURE) and the Remicade (inflixi-
mab) registry, respectively. In STURE, demographic data,
disease characteristics, and evaluations of disease activity
are registered for all patients with RA treated with biolo-
gics in the Karolinska University Hospital, Stockholm.
Disease activity measures are performed at inclusion, at
3, 6 and 12 months after treatment start, and every
6 months thereafter. The Remicade registry is kept at the
same hospital and includes patients with IBD treated
with infliximab. Data files were extracted from these two
registries, and missing measurements were manually
retrieved from the hospital patient information system.
Since 2007, data on nearly all patients with psoriasis in
Sweden given systemic treatment, including biologic
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agents, have been kept in a nationwide database called
PsoReg. Data from this registry were obtained from the
published annual report of 2010 [16].
Assessments
For patients with RA or IBD, basic demographic data,
including gender and disease activity measures were col-
lected at a single time point, just before the initiation of
the first biologic therapy; for psoriasis, data were col-
lected at time of inclusion in PsoReg. For RA, disease
activity was assessed by the Disease Activity Score with a
28-joint count (DAS28). The DAS28 computes a single
score from four separate measurements (tender joint
count (TJC), swollen joint count (SJC), patient assess-
ment of global disease activity by visual analog scale
(VAS), and erythrocyte sedimentation rate (ESR)) [21].
For the patients who had C-reactive protein (CRP) mea-
sured, the DAS28-CRP was also computed, with a high
score indicating more active disease. ESR (mm/h) and
CRP (mg/l) comprised the acute phase reactants mea-
sured. The SJC and TJC, respectively, were counted using
the standard set of 28 joints. Experienced general pain
was rated by the patients on a VAS of 0 to 100 mm. Both
patients and physicians had to rate the global disease
activity. Patients used a 100 mm VAS (0 = inactive and
100 = strongly active RA), while the doctors used a six-
point scale, ranging from 0 (no activity) to 5 (maximum
activity). Functional status was measured using the Swed-
ish version of the Stanford HAQ disability index. The
HAQ scores range from 0 to 3, with a higher score indi-
cating a higher level of disability [22]. For a subgroup of
patients, HRQOL was measured using the EuroQol five
dimensions utility score (EQ-5D), which is summarized
in a single number which ranges from 0 (death) to 1 (full
health), but negative scores are also possible [23,24].
The disease activity measurements used for IBD were
hemoglobin (Hb) level (g/l), ESR, CRP, the Harvey-Brad-
shaw Index (HBI) and the Short Health Scale (SHS). The
HBI is a tool for measuring disease activity, which is com-
pleted by both patient (general wellbeing, abdominal pain,
and number of liquid stools per day) and physician (based
on palpable abdominal mass and presence of complica-
tions). The sum of all single scores is used as the outcome
measure, and a higher score indicates more active disease
[25]. The SHS was used to measure HRQOL. It consists of
four questions relating to severity of symptoms, influence
of the disease on daily life, concern about the disease, and
general wellbeing, which are all answered by the patient
using a 100 mm VAS. Scores from all four questions are
separate outcomes, and a higher score represents a worse
HRQOL [26,27].
For psoriasis, two different measures were used: the
Psoriasis Area and Severity Index (PASI) and the Derma-
tology Life Quality Index (DLQI). The PASI is a clinical
measurement that takes into account both the extent and
the severity of the skin symptoms; scores range from 0 (no
psoriasis activity) to 72 points (maximal psoriasis activity).
The DLQI is a 10-item dermatology-specific QOL mea-
surement that assesses the effect of skin disease on a
patient’s HRQOL over a 7-day period. The total score
ranges from 0 to 30, with higher scores indicating worse
HRQOL [28]. For both the DLQI and PASI, more than 10
points is considered a high score [16,29]. In the annual
report, no distinction was made between the different
treatment groups for both PASI and DLQI. Thus the data
given in this study apply to the total group of patients with
psoriasis treated with systemic medication (that is, the
worst cases), which also includes non-biologic systemic
treatment. The different parameters are summarized in
table 1.
Statistical analysis
Statistical analysis was performed using SPSS statistical
software (version 19.0; SPSS Inc., Chicago, IL, USA). To
compare differences between men and women, the
Mann-Whitney U-test or the independent samples t-test
was used for continuous variables, and the c2 test for
proportions. For RA and psoriasis, the proportions of
men and women prescribed the different biologic drugs
were compared within each disease group. Differences in
disease characteristics between man and women were
evaluated for RA, IBD, and psoriasis separately, and for
each biologic in RA. All significance tests were two-tailed
and P<0.05 was considered significant.
Results
Rheumatoid arthritis
In total, 1912 patients with RA (402 men (21%) and
1510 women (79%)) were assessed for the study. They
received as a first biologic either a TNF-blocking agent
(etanercept, adalimumab, infliximab, certolizumab pegol,
or golimumab) or a non-TNF-blocking agent (anakinra,
rituximab, abatacept, or tocilizumab). The demographic
and clinical characteristics of the cohort are shown in
table 2. When biologic treatment was started for the
first time in each patient, significant differences between
men and women were found for ESR, patient global
assessment, TJC, HAQ, DAS28, and DAS28-CRP. All
these outcome values were higher in women than in
men, with P-values ranging between 0.00 and 0.02. By
contrast, the physician global assessment and CRP were
the same for both genders, and the SJC was numerically,
but not significantly, higher in males. General pain
scores were somewhat higher in females compared with
males, but the difference did not reach significance.
There was no difference between genders in age at
treatment start, but women had a slightly longer disease
duration (P = 0.06).
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Most patients were prescribed a TNF-blocking agent
as their first biologic drug, with etanercept, adalimumab,
and infliximab being the most frequently prescribed, but
no significant differences were seen in the proportions
of men and women prescribed any of the nine different
biologics (data not shown). Similar percentages of men
and women received concurrent therapy with glucocor-
ticoids, non-steroidal anti-inflammatory drugs, or con-
ventional DMARDs. All biologic agents were analyzed
separately for gender differences in disease activity para-
meters; significant differences similar to those in the
total group of RA patients were found only for etaner-
cept, adalimumab, and infliximab (data not shown).
Gender differences were also analyzed separately for the
year in which treatment was started, and a similar pat-
tern to that of the total group of patients with RA was
seen (data not shown).
Thus, in RA the female:male proportion of biologics
prescribed reflects the overall prevalence of the disease,
and objective disease activity parameters were similar
between the sexes, but subjective experiences of the dis-
ease were significantly worse at this time point in female
patients. The compound indices DAS28 and DAS28CRP
showed significant differences that were also driven
mostly by the subjective components TJC and patient
global assessment of disease activity.
Inflammatory bowel disease
There were 131 patients with IBD, and all had received
infliximab as their first biologic. Most of the patients were
men (69.5%), and most had CD (82.4%) or UC (15.3%); the
remaining 2.3% of the patients had another form of IBD.
Mean age at treatment start was the same for men and
women (34.4 versus 35.4 respectively, P = 0.71) and there
was also no gender difference in disease duration. The
clinical characteristics are shown in Figure 1. No signifi-
cant differences between men and women were found for
any parameters. Although the hemoglobin level for men
was higher than that for women, this appeared to reflect
the physiological sex difference, as there was no gender
difference seen in the proportions of men and women hav-
ing laboratory-defined anemia (data not shown). Male and
female patients who were started on biologic treatment
had similar values on the HBI, but on three out of four
questions of the SHS women had numerically higher
scores, although these differences did not reach statistical
significance. The disease characteristics were also evalu-
ated for CD and UC separately, which resulted in the
Table 1 Parameters for disease activity in rheumatoid arthritis, inflammatory bowel disease and psoriasis
Measurement Definition
Rheumatoid arthritis
Swollen joint count (SJC) Number of swollen joints as determined by the physician out of a standard set of 28 joints
Tender joint count (TJC) Number of joints tender to palpation (as for SJC)
Patient assessment of pain Measured by 100 mm visual analog scale (VAS)
Patient assessment of global
disease activity
Measured by 100 mm VAS
Physician assessment of global
disease activity
Measured on a six-point scale ranging from ‘no activity’ to ‘maximum activity’
Acute phase reactant ESR (mm/h) and/or CRP (mg/l)
Health Assessment questionnaire
(HAQ)
Assessment of functional status (0 to 3 points)
EuroQol five dimensions utility
score (EQ-5D)
Assessment of health-related quality of life (HRQOL) (0 to 1)
Disease Activity Score (DAS28) Assessment of disease activity computed using SJC, TJC, ESR and patient assessment of global disease
activity, based on 28 joints. Termed DAS28-CRP when CRP is used instead of ESR
Inflammatory bowel disease
Hemoglobin level Measure in g/l
Acute phase reactant ESR (mm/h) and/or CRP (mg/l)
Harvey Bradshaw Index (HBI) Assessment of disease activity completed by both patient and physician
Short Health Scale (SHS) Assessment of HRQOL in four domains, measured by 100 mm VAS
Psoriasis
Psoriasis Area and Severity Index
(PASI)
Assessment of extent and severity of skin lesions consisting of four components; scaling, redness, extent and
elevation (0 to 72 points)
Dermatology Life Quality Index
(DLQI)
Assessment of the effect of skin disease on HRQOL (0 to 30 points)
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein
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same pattern as for the total group (data not shown).
Thus, in IBD, both men and women had similar disease
severity as measured by the HBI at the start of biologic
therapy, but there was a numerical trend suggesting that
female patients experience more symptoms.
Psoriasis
In total, 2450 patients were enrolled in PsoReg, and all
had received a form of systemic treatment, with 589
patients (26.0%) being treated with biologic medications.
In both the overall group and the biologic treatment
group, most of the patients were men (60.0% and 67.1%
respectively). In the whole group, approximately 600
patients (24.5%) were between 31 and 45 years old and
800 (32.7%) between 45 and 60 years; more specific data
about mean age or disease duration were not stated in
the report. Significantly more men than women had a
high score on the PASI, whereas for the DLQI the
reverse pattern was seen, with significantly more women
having a score of greater than 10 points. The differences
are summarized in Figure 2. The same proportions of
men and women were prescribed etanercept, adalimu-
mab, and infliximab; only for ustekinumab was a signifi-
cant gender difference seen (women 7.7%, men 2.5%;
P = 0.01).
Discussion
In this study, we investigated gender differences in bio-
logic treatment by examining disease characteristics at
the time of biologic initiation in RA, IBD, and psoriasis.
We found that there was a treatment difference in both
IBD and psoriasis, with men receiving biologic medica-
tion more often than women. With regard to the disease
characteristics, we found that women with RA or IBD
had higher scores than men on subjective but not on
objective measures. Only for psoriasis did men score
higher on objective disease measurements.
Thus, the greater proportion of men receiving biologic
treatment for IBD or psoriasis compared with women
was not reflected in the population prevalence rates,
which were similar for both sexes in both diseases. This
in contrast to RA, for which treatment and population
male:female ratios matched each other. For RA, our data
confirm earlier studies that did not note any gender dif-
ferences in the overall use of biologic medications
Table 2 Demographic and clinical characteristics just
before treatment start in patients with rheumatoid
arthritis
Parameter Men Women P value
Patients, n (%) 402 (21%) 1510 (79%)
Age at treatment start, years 54.7 (13.7) 54.6 (14.5) 0.93
Disease duration, years 14.7 (10.8) 15.9 (11.2) 0.06
ESR, mm/h 30.1 (21.9) 33.1 (23.3) 0.022,3
CRP, mg/l 25.5 (30.1) 24.9 (31.4) 0.73
Physician global assessment 2.2 (0.8) 2.3 (0.7) 0.38
Patient global assessment 54.3 (24.3) 58.7 (24.1) 0.00*
Pain 54.8 (23.9) 56.9 (24.2) 0.16
Swollen joint count 9.1 (5.9) 8.8 (5.5) 0.36
Tender joint count 7.8 (6.3) 8.7 (6.1) 0.013,4
HAQ 1.13 (0.68) 1.34 (0.68) 0.003,4
DAS28 5.07 (1.37) 5.39 (1.21) 0.003,4
DAS28-CRP 4.87 (1.25) 5.06 (1.14) 0.013,4
EQ-5D 0.49 (0.36) 0.50 (0.30) 0.89
Abbreviations: ESR, erythrocyte sedimentation rate; CRP, C-reactive protein;
HAQ, Health Assessment Questionnaire; DAS28, Disease Activity Score using
28 joints; DAS28-CRP, DAS28 using CRP; EQ-5D, EuroQol five dimensions utility
score.




Figure 1 Clinical characteristics just before treatment start in
patients with inflammatory bowel disease (IBD). Values are
means, and significant values are indicated by brackets. CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate; Hb,
hemoglobin level; SHS, Short Health Scale.
Figure 2 Proportions of high Psoriasis Area and Severity Index
(PASI) and Dermatology Life Quality Index (DLQI) scores in
patients with psoriasis. Values are proportions, and significant
values are indicated by brackets.
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[5,7,30,31]. For both psoriasis and IBD, it had previously
been suggested that males are more likely than women to
receive systemic treatment (biologic or non-biologic)
[32,33], and in the case of psoriasis that female patients
are more likely to receive topical treatment whereas men
are more likely to receive phototherapy [34].
The gender difference we found in treatment propor-
tions for men and women with IBD or psoriasis gives rise
to a number of hypotheses that could explain these find-
ings. Possible reasons that more men than women are
treated with biologics include the following: men have
more severe disease activity; men may be more likely
than women to express treatment preferences for biolo-
gics/systemic agents; there may be gender differences in
treatment access; the risk:benefit ratio as determined by
the physician may be modified by the patient’s gender; or
there may be a gender difference in the effectiveness of
biologicals and of treatment alternatives. With respect to
the last point, an interesting point was made by Nyberg
et al., who suggested that females are more likely to
believe that they can influence their disease themselves
and therefore tend to assume or be given greater respon-
sibility for their disease (that is, are prescribed more self-
care topical treatment) [34]. Later in-depth interviews
showed the same tendency [35]. This could mean that
through more and better use of an alternative treatment,
women with psoriasis need biologic treatment less often
than men. Because some patients in this psoriasis cohort
were already using biologics at inclusion, similar effects
with better adherence to oral medication by women
might have influenced PASI scores. However, to our
knowledge no reports exist to support this hypothesis.
With regard to the risk:benefit ratio, biologic therapies
might be considered more dangerous for young women
of childbearing age than for men because of possible tera-
togenic effects, although for biologics this is not yet pro-
ven [36,37]. This concern, in combination with age
differences, might have been an influence on the discre-
pant gender ratio for biologic treatment in IBD and psor-
iasis, as the female patients with RA were on average
20 years older than their IBD and psoriasis counterparts
when started on biologics (54.6 for RA versus 35.4 years
for IBD and between 20 and 40 years for psoriasis [13]).
With regard to the disease characteristics pertaining
before biologic therapy initiation, significant gender dif-
ferences were found for both RA and psoriasis, and
similar numerical differences were found for IBD. At
treatment start, female patients with RA had higher
values for ESR, patient global assessment, TJC, HAQ,
DAS28, and DAS28CRP compared with men. One study
on anti-TNF therapy [38] found a similar gender imbal-
ance in objective and subjective measurements as we
found in this study. Furthermore, recent data from
Arkema et al, from the Anti-Rheumatic Therapies in
Sweden (ARTIS) registry also support a difference in
subjective disease parameters for patients with RA start-
ing biologic therapy.[39] Most studies on gender in RA
used time points other than biologic initiation, but the
results parallel ours [3-6,40].
Because biologic medications are now used earlier in
the disease course than at the time these therapies were
first introduced, this could possibly induce gender differ-
ences. However, we did not find such evidence, and this
is in line with similar studies [39]. The differences in TJC
and SJC are not large, they could nonetheless be impor-
tant when studied at group level. Furthermore, measure-
ments of TJC and SJC in rheumatology practice in the
hospital system in which these patients were seen are
highly standardized (based on the European League
Against Rheumatism handbook) so that interobserver
variability is minimized. Another confounder could be a
gender difference in the specific joints that are inflamed,
but as the individual joints are not recorded in the
STURE database, this question remains open.
In psoriasis, a gender difference was found for both
the PASI and the DLQI, with men more often having
high PASI scores and women more often having high
DLQI scores. Our findings for the DLQI parallel a few,
but not all, studies on QOL in psoriasis [18-20,41]. For
IBD, the SHS, which can be regarded as a short QOL
assessment, tended to be higher in women. This
matches earlier research in which female gender was
found to be a predictor of impaired HRQOL and level
of concern [42-44].
Although different assessments were used for the
three diseases, a general comparison can be made in
that in all three diseases the gender imbalance seems to
occur only in subjective measurements such as pain,
functional status, and QOL. These results support the
hypothesis that the inherent biology of the diseases is
similar for both genders, but that females experience
their illness as worse, and consequently have a higher
symptomatic disease burden. For RA, this is further sup-
ported by a study in which women were shown to have
more symptoms than men despite similar radiographic
joint damage [30]. The higher ESR in female patients
with RA could be an exception, but women are known
to have higher ESR levels than men, which is most likely
due to hormonal factors and a difference in hematocrit
concentration [39,45].
The literature regarding gender differences in RA has
focused on the possible non-sex neutrality of the disease
activity measurements used. For psoriasis and IBD, the
same questions may apply. Pain and related measure-
ments are often discussed as being non-sex-neutral.
Women are more likely than men to experience differ-
ent kinds of recurrent pains and also to report more
severe levels of pain [46,47]. Moreover, with the same
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noxious stimuli, women experience more pain than men
[48]. These factors can consequently influence pain
measurements (TJC, global pain), assessments in which
pain is included (DAS28, SHS symptoms, HBI) or
assessments that are affected by pain (HAQ, DLQI,
SHS). In the case of RA, concomitant fibromyalgia
could also influence pain measurements [49].
Another example is the HAQ score, which is known
to be higher in females with RA [5,6,30,50]; and this
could be attributable to the fact that women have less
muscle strength, but it is also possible that men overes-
timate their functional capacity or that women have
higher pain scores [30,48]. Therefore the higher HAQ
scores might be caused by the properties of the HAQ
rather than by RA; however, it is interesting to note that
in the healthy population, no sex differences in HAQ
scores are seen [51,52].
Although not formally studied, the PASI might also be
influenced by gender. The component of ‘scaling’ is
immediately improved after the use of emollients, and
even experienced scorers would probably give a lower
score for a skin that has just been treated with emolli-
ents. As stated earlier, women are more likely than men
to adhere to topical treatment, and consequently, this
could mean systematic underscoring of the PASI in
female patients.
Thus, it is not clear whether standard disease assess-
ments are sex-neutral, but there is also another way of
looking at this question. For example, if women do feel
more pain with the same stimulus can it then really be
said that the disease is the same? Are fewer compensation
resources sufficient reason to disregard a gender differ-
ence? It would seem that the subjective disease experience
may to some extent be discounted by physicians, whereas
for the patient this may be the most important part of
their disease.
In summary, we found gender differences in disease
characteristics at the start of biologic or systemic treat-
ment in RA, IBD, and psoriasis, with an over-representa-
tion of men in the latter two diseases, and greater effect
of the disease and worse QOL scores in women with all
three diseases. This suggests a potential subtle under-
treatment of women with these diseases. We note that
undertreatment in RA might then also partly explain the
worse outcomes previously reported in longitudinal
studies for women with RA.
This study has several limitations, as it was a retrospec-
tive observational study with all data having been col-
lected at clinical visits. In addition, it must be noted that
the psoriasis results came from an annual report, and
were not computed using the raw data. Furthermore,
some of the measurements in psoriasis were performed
after treatment initiation, and thus the real gender differ-
ence might therefore be even bigger. The PASI and
DLQI scores were given only for the total group, and not
separately for each treatment, therefore subgroup analysis
was not possible, thus making comparison with RA and
IBD more difficult.
Conclusion
Women with RA or psoriasis scored significantly higher
than men on subjective, but not objective, disease activ-
ity measures. A similar trend was seen for IBD. This
indicates that all three diseases have a greater effect on
women than on men at the same level of treatment.
These findings might suggest that in all three diseases,
subjective measures are discounted to some extent in
the therapeutic decision-making process, which could
indicate undertreatment in female patients.
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